Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (273)
Related Products (273)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
Avitinib dihydrochloride
0 ImagesCat. No.: HY-183397CAS No.: 1557268-90-2Synonyms: Abivertinib dihydrochloride; AC0010 dihydrochlorideAvitinib (Abivertinib) dihydrochloride is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib dihydrochloride is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib dihydrochloride shows anticancer effects. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
PF-06465469 (Standard)
0 ImagesCat. No.: HY-108691RCAS No.: 1407966-77-1PF-06465469 (Standard) is the analytical standard of PF-06465469 (HY-108691). This product is intended for research and analytical applications. PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
(R)-Elsubrutinib (Standard)
0 ImagesCat. No.: HY-109143BRCAS No.: 1643570-23-3Synonyms: (R)-ABBV-105 (Standard)(R)-Elsubrutinib (Standard) is the analytical standard of (R)-Elsubrutinib (HY-109143B). This product is intended for research and analytical applications. (R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Evobrutinib (Standard)
0 ImagesCat. No.: HY-101215RCAS No.: 1415823-73-2Synonyms: M2951 (Standard); MSC2364447C (Standard)Evobrutinib (Standard) is the analytical standard of Evobrutinib (HY-101215). This product is intended for research and analytical applications. Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ACP-5862-d4
0 ImagesCat. No.: HY-135334SACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Btk inhibitor 2 (Standard)
0 ImagesCat. No.: HY-101766RCAS No.: 1558036-85-3 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
(R)-Zanubrutinib (Standard)
0 ImagesSynonyms: (R)-BGB-3111 (Standard)(R)-Zanubrutinib (Standard) is the analytical standard of (R)-Zanubrutinib (HY-101474B). This product is intended for research and analytical applications. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib (HY-101474A). (R)-Zanubrutinib inhibits Bruton's tyrosine kinase (Btk) with an IC50 of 11 nM. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Tolebrutinib (Standard)
0 ImagesCat. No.: HY-109192RCAS No.: 1971920-73-6Synonyms: SAR442168 (Standard); PRN2246 (Standard)Tolebrutinib (SAR442168) (Standard) is the analytical standard of Tolebrutinib (HY-109192). This product is intended for research and analytical applications. Tolebrutinib (SAR442168) is an orally active, selective, and blood-brain barrier-penetrant BTK inhibitor with neuroactive properties. Tolebrutinib is being investigated for use in multiple sclerosis (MS), particularly secondary progressive multiple sclerosis (SPMS). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- BTK inhibitor 8
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Spebrutinib besylate
0 ImagesCat. No.: HY-18012ACAS No.: 1360053-81-1Synonyms: AVL-292 benzenesulfonate; CC-292 besylateSpebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
BMS-986142 (Standard)
0 ImagesCat. No.: HY-101856RCAS No.: 1643368-58-4BMS-986142 (Standard) is the analytical standard of BMS-986142 (HY-101856). This product is intended for research and analytical applications. BMS-986142 is a potent and highly selective reversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 0.5 nM. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CGI 560
0 ImagesCat. No.: HY-18016CAS No.: 845269-74-1CGI 560 is an inhibitor for Bruton's tyrosine kinase (BTK) with an IC50 of 400 nM. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Ibrutinib Racemate (Standard)
0 ImagesCat. No.: HY-10997ARCAS No.: 936563-87-0Synonyms: PCI-32765 Racemate (Standard)Ibrutinib (Racemate) (Standard) is the analytical standard of Ibrutinib (Racemate). This product is intended for research and analytical applications. Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results